Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics announces the successful completion of the first milestone under Phase 2 in its partnership with Hologic, Inc. to develop a new fetal fibronectin test for pre-term birth detection. The milestone, part of a US$4.7 million agreement, comes with a US$0.3 million award from Hologic and signals progress in adapting the test for Lumos’s proprietary reader platform. The company underscores the significance of the fFN test in the US pre-term diagnostic market and commits to updating stakeholders as further milestones are achieved.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
